arrow
U

Ugo De Giorgi

university oncology unit
H指数:79
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy

基线血清癌胚抗原(CEA)是接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的独立预后生物标志物

2026-09-110
OAAI
Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Prognostic impact of variants of uncertain significance (VUS) in BRCA genes and homologous recombination repair (HRR) genes in prostate cancer: a real-world multicenter study

BRCA基因和同源重组修复(HRR)基因中意义不明的变异(VUS)对前列腺癌预后的影响:一项真实世界多中心研究

2026-08-040
OA
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial

使用恩扎卢胺联合醋酸亮丙瑞林治疗高风险生化复发的前列腺癌:EMBARK试验的次要终点

2026-05-016
PRE
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

177Lu-PSMA-617放射性配体疗法的疗效、毒性和临床结局:一项前瞻性、单臂、II期研究,研究对象为每周期接受5.5 GBq剂量的晚期去势抵抗性前列腺癌患者

2025-11-270
OAAI
Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]

勘误:Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 的安全性分析,来自随机、安慰剂对照、III 期 TALAPRO-2 研究的结果 [European Journal of Cancer Volume 213, December 2024, 115078]

2025-11-130
PRE
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)

卡博替尼在转移性肾细胞癌一线治疗中的真实世界应用:CabFRONT研究(Meet-URO 24)

2025-10-130
OAAI
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

纳武利尤单抗联合卡博替尼治疗转移性肾细胞癌:国际ARON-1研究的真实世界证据

2025-07-270
OA
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果:来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据

2025-07-160
PRE
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 HRR 缺陷型转移性去势抵抗性前列腺癌的男性患者:来自随机、安慰剂对照的 III 期 TALAPRO-2 试验的最终总生存结果

2025-07-160
PRE
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

恩诺单抗维多汀联合帕博利珠单抗对比化疗在先前未经治疗的局部晚期或转移性尿路上皮癌患者中的疗效(EV-302):一项开放标签、随机对照、III期研究的患者报告结局

2025-05-280
PRE
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study☆

帕博利珠单抗联合恩扎卢胺和雄激素剥夺疗法与安慰剂联合恩扎卢胺和雄激素剥夺疗法治疗转移性激素敏感性前列腺癌:随机、双盲、III期KEYNOTE-991研究☆

2025-05-160
PREAI
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study

真实世界中接受辅助紫杉醇联合曲妥珠单抗(APT)方案治疗的I期HER2阳性早期乳腺癌患者的5年结果:一项国际回顾性研究

2025-05-150
PRE
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

帕博利珠单抗联合仑伐替尼在转移性肾细胞癌患者中的应用:国际ARON-1研究的真实世界证据

2025-05-090
OA